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commendations for the management of dyslipidemia.1–7
Although many commonalities exist among them, material
differences are present as well. The leadership of the
National Lipid Association (NLA) convened an Expert
Panel to develop a consensus set of recommendations for
patient-centered management of dyslipidemia in clinical
medicine.
The current Executive Summary highlights the major
conclusions in Part 1 of the recommendations report of
the NLA Expert Panel. The Executive Summary does not
include a comprehensive reference list, but citations have
been included for several key publications. The full
report will include additional details on the rationale
for the recommendations and citations to published
research considered in the panel’s deliberations. A pre-
sentation containing the main elements of these recom-
mendations was made available to the public and other
organizations involved with the prevention of atheroscle-
rotic cardiovascular disease (ASCVD) to solicit input
during an open comment period. Comments and sugges-
tions were received from many members of the NLA as
well as other individuals and organizations and were
collated for consideration and adjudication by the panel
in formulating the final set of recommendations contained
herein.
Part 1 of the NLA Expert Panel Recommendations for
Patient-Centered Management of Dyslipidemia, will cover:
 Background and conceptual framework for formulation
of the NLA Expert Panel recommendations;
 Screening and classification of lipoprotein lipid levels in
adults;
 Targets for intervention in dyslipidemia management;
 ASCVD risk assessment and treatment goals based on
risk category;
 Atherogenic cholesterol—non–high-density lipoprotein
cholesterol (non-HDL-C) and low-density lipoprotein
cholesterol (LDL-C)—as the primary targets of therapy;
and
 Lifestyle and drug therapies intended to reduce morbidity
and mortality associated with dyslipidemia.
Part 2 is in development and will cover the following
topics:
 Lifestyle therapies;
 Groups with special considerations:
B Children, adolescents, pregnant women, and older
patients;
B Gender and ethnic differences;
B Patients with congestive heart failure;
B Patients with human immunodeficiency virus;
B Patients with selected chronic inflammatory states and
immune disorders;
B Patients with residual risk despite statin therapy;
 Strategies to assist with patient adherence; and
 Team-based collaborative care.Background and conceptual framework for
formulation of the NLA Expert Panel
recommendations
Clinical decisions often need to be made in the absence
of ideal or complete evidence, and well-informed experts
will not always evaluate or interpret the evidence base in
the same way. Clinical recommendations aim to assist
clinicians in making decisions about the best strategies for
management of a condition, taking into account potential
benefits and risks of the available options. An overarching
principle in the NLA Expert Panel recommendations is that
they are intended to inform, not replace, clinical judgment.
A patient-centered approach dictates that clinical judgment
take into account the circumstances, objectives, and prefer-
ences of each individual patient.7,8 The patient should be an
active participant in the process, having engaged with the
clinician in a dialogue about the objectives of therapy,
including potential risks and side effects as well as benefits
and costs. When patients understand and participate in
decisions to select specific treatment strategies, this tends
to enhance commitment to long-term adherence.
The NLA recognizes the major contribution that dysli-
pidemia management has made to the progressive reduction
in ASCVD morbidity and mortality that has been observed
during the past decade.9 This reduction in risk occurred
under the guidance provided by previous documents,
most notably the National Cholesterol Education Program
(NCEP) Adult Treatment Panel III (ATP III) Guidelines.1,10
The NLA Expert Panel consensus view is that the evidence
that has accumulated since the 2004 update of the NCEP
ATP III guidelines warrants a modest refinement of previ-
ous lipid-related risk management strategies, as outlined
in the present report.
The evidence base considered in the development of
consensus for these recommendations emphasized results
from randomized controlled trials (RCTs) to evaluate in-
terventions on clinical ASCVD events (mainly myocardial
infarction, coronary death, and stroke), including subgroup
assessments and pooled analyses from multiple trials, where
available. Although the panel acknowledges that the primary
results from RCTs represent the strongest evidence from
which to draw conclusions about benefits and risks of
treatment strategies, it also recognizes that the available
RCT evidence has limitations, and is often incomplete, or of
uncertain relevance to patients with characteristics that may
differ in important ways from those who participated in
the RCTs. Therefore, evidence from epidemiological and
genetic studies as well as metabolic and mechanistic in-
vestigations has also been considered.
Major conclusions of the NLA Expert Panel
The NLA Expert Panel found the evidence to be
compelling to support the following conclusions, which
guided the development of the recommendations.
Table 1 Classifications of cholesterol and triglyceride Levels
in mg/dL
Non-HDL-C*
,130 Desirable
130–159 Above desirable
160–189 Borderline high
190–219 High
$220 Very high
LDL-C
,100 Desirable
100–129 Above desirable
130–159 Borderline high
160–189 High
$190 Very high
HDL-C
,40 (men) Low
,50 (women) Low
Triglycerides
,150 Normal
150–199 Borderline high
200–499 High
$500 Very high†
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein
cholesterol.
*Non-HDL-C 5 total cholesterol minus HDL-C.
†Severe hypertriglyceridemia is another term used for very high tri-
glycerides in pharmaceutical product labeling.
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apolipoprotein (apo) B-containing lipoproteins (non–
HDL-C and LDL-C, termed atherogenic cholesterol) is
a root cause of atherosclerosis, the key underlying pro-
cess contributing to most clinical ASCVD events.
2. Reducing elevated levels of atherogenic cholesterol will
lower ASCVD risk in proportion to the extent that
atherogenic cholesterol is reduced. This benefit is pre-
sumed to result from atherogenic cholesterol lowering
through multiple modalities, including lifestyle and
drug therapies.
3. The intensity of risk-reduction therapy should generally
be adjusted to the patient’s absolute risk for an ASCVD
event.
4. Atherosclerosis is a process that often begins early in
life and progresses for decades before resulting in a clin-
ical ASCVD event. Therefore, both intermediate-term
and long-term/lifetime risk should be considered when
assessing the potential benefits and hazards of risk-
reduction therapies.
5. For patients in whom lipid-lowering drug therapy is
indicated, statin treatment is the primary modality for
reducing ASCVD risk.
6. Non-lipid ASCVD risk factors should also be managed
appropriately, particularly high blood pressure, cigarette
smoking, and diabetes mellitus.
Importance of lifestyle therapies
An additional tenet of the NLA Expert Panel recommen-
dations is the centrality of lifestyle therapies to ASCVD
prevention. The application of pharmacotherapy to dyslipi-
demia management has been enormously successful. Many
large-scale RCTs, involving, in aggregate, hundreds of
thousands of participants, have shown that drug therapies
(particularly statins) that lower atherogenic cholesterol
levels are effective for reducing ASCVD morbidity and
mortality. However, results from observational studies also
strongly suggest that lifestyle habits have an important
impact on atherogenic cholesterol levels as well as other
related disturbances such as obesity, hypertension, and
insulin resistance. Thus, although drug therapy may be
needed in those with sufficient risk, the NLA Expert Panel’s
consensus view was that lifestyle therapies are an important
element of risk-reduction efforts, whether or not drug
therapy is also used.
Usefulness of treatment goals
Most RCTs of lipid-lowering drug therapies have tested
drug treatment against a placebo control, or a more intensive
with a less-intensive treatment regimen. The strategy of
treating patients to a specific level of LDL-C or non-HDL-C
has not been tested in any of the large trials assessingASCVD
morbidity and mortality. Nevertheless, taken together, re-
sults from RCTs that have employed various methods for
lowering atherogenic cholesterol (pharmacotherapy, diet,ileal bypass surgery) have indicated that lower on-treatment
levels have been consistently associated with lower absolute
risk for an ASCVD event.5,11 These findings align with
results from observational studies that suggest a log-linear
relationship between the levels of atherogenic cholesterol
and absolute ASCVD event risk.
The Expert Panel’s consensus view is that treatment
goals are useful as means to ensure that the aggressiveness
of therapy to lower atherogenic cholesterol is matched
to absolute risk for an event. Moreover, treatment goals
facilitate effective communication between patients and
clinicians, providing an easily interpretable means through
which the clinician can communicate progress toward
meeting treatment objectives, thus supporting efforts to
maximize long-term adherence to the treatment plan.Screening and classification of initial
lipoprotein lipid levels
In all adults ($20 years of age), a fasting or nonfasting
lipoprotein profile should be obtained at least every 5 years.
At a minimum, this should include total cholesterol
and HDL-C, which allows calculation of non-HDL-C (total
cholesterol minus HDL-C). If fasting (generally 9 to
12 hours), the LDL-C level may be calculated, provided
that the triglyceride concentration is ,400 mg/dL. Classi-
fications for lipoprotein lipid levels are shown in Table 1.
476 Journal of Clinical Lipidology, Vol 8, No 5, October 2014Lipoprotein lipid levels should be considered in conjunc-
tion with other ASCVD risk determinants to assess treat-
ment goals and strategies, as covered later in this report.
If atherogenic cholesterol levels (non-HDL-C and
LDL-C) are in the desirable range, lipoprotein lipid mea-
surement and ASCVD risk assessment should be repeated in
5 years, or sooner based on clinical judgment. Examples of
changes that might prompt earlier rescreening include
changes in ASCVD risk factors (including weight gain), a
premature ASCVD event in a first-degree relative, evidence
of ASCVD in the patient, or a new potential secondary cause
of dyslipidemia. For those with atherogenic cholesterol
in the desirable range, public health recommendations
regarding lifestyle should be emphasized.Table 2 Treatment goals for non-HDL-C, LDL-C, and Apo B in
mg/dL
Risk Category
Treatment Goal
Non-HDL-C LDL-C Apo B*
Low ,130 ,100 ,90
Moderate ,130 ,100 ,90
High ,130 ,100 ,90
Very High ,100 ,70 ,80
Apo, apolipoprotein; LDL-C, low-density lipoprotein cholesterol;
non-HDL-C, non–high-density lipoprotein cholesterol.
*Apo B is a secondary, optional target of treatment.Targets of intervention in dyslipidemia
management
Non-HDL-C and LDL-C
When intervention beyond public health recommenda-
tions for long-term ASCVD risk reduction is employed,
levels of atherogenic cholesterol (non-HDL-C and LDL-C)
should be the primary targets for therapies. LDL-C com-
prises w75% of the cholesterol in circulation carried by
lipoprotein particles other than HDL, although this percent-
age may be lower in those with hypertriglyceridemia.
Although LDL-C has traditionally been the primary
target of therapy, the NLA Expert Panel’s consensus view is
that non-HDL-C is a better primary target for modification
than LDL-C. Non-HDL-C comprises the cholesterol carried
by all potentially atherogenic particles, including LDL,
intermediate density lipoproteins, very low-density lipo-
proteins (VLDL) and VLDL remnants, chylomicron rem-
nants, and lipoprotein (a). Epidemiological studies have
shown that non-HDL-C is a stronger predictor of ASCVD
morbidity and mortality than LDL-C.12 Pooled analyses of
data from intervention studies have shown that non-HDL-C
changes and levels during treatment are more strongly asso-
ciated with risk for coronary heart disease (CHD) than
changes in LDL-C or on-treatment levels of LDL-C.13,14
Moreover, when on-treatment values are discordant (i.e.,
only 1 of the 2 is elevated), risk is more closely aligned
with non-HDL-C than LDL-C.14
Possible explanations for the superiority of non-HDL-C
over LDL-C for predicting ASCVD event risk include: (1) as
with LDL, some triglyceride-rich lipoprotein remnants enter
the arterial wall, and thus contribute to the initiation and
progression of atherosclerosis, (2) non-HDL-C correlates
more closely than LDL-C with apo B, thus more closely
correlates with the total burden of atherogenic particles, and
(3) elevated levels of triglycerides and VLDL-C reflect
hepatic production of particles with greater atherogenic
potential, such as those having poor interactivity with hepatic
receptors, resulting in longer residence time in the circulation.Although both non-HDL-C and LDL-C are termed
atherogenic cholesterol, non-HDL-C is listed first to empha-
size its primary importance. Both non-HDL-C and LDL-C
are considered targets for lipid-altering therapy, and goals
for therapy have been defined for both (Tables 2 and 3).
Using non-HDL-C as a target for intervention also simpli-
fies the management of patients with high triglycerides.
Non-HDL-C incorporates the triglyceride level indirectly,
because the triglyceride concentration is highly correla-
ted with the VLDL-C concentration. Goal levels of non-
HDL-C may be attained by targeting either or both of the
main components of non-HDL-C: LDL-C and VLDL-C.
However, it should be emphasized that goal thresholds apply
to non-HDL-C and LDL-C, because discordance may occur,
and effective management of atherogenic cholesterol would
ideally result in achieving goal levels for both.
Desirable levels of atherogenic cholesterol for primary
prevention (ie, those without clinical evidence of ASCVD or
other very high-risk conditions) are ,130 mg/dL for non-
HDL-C and ,100 mg/dL for LDL-C (Tables 2 and 3). Sup-
port for these thresholds derives primarily from population
studies showing low ASCVD incidence rates in groups with
levels in these ranges, including those with genetic variants
that result in below-average levels of atherogenic cholesterol
throughout life.15 These levels are further supported by data
from RCTs showing that risk for ASCVD events is reduced
with a variety of atherogenic cholesterol-lowering interven-
tions, including cholesterol-lowering drugs and dietarymodi-
fication, in a pattern that is generally consistent with
expectations based on observational evidence.5,16–19
Apo B
Apo B is considered an optional, secondary target for
treatment. Epidemiological studies have generally shown
that both apo B and non-HDL-C are better predictors of
ASCVD risk than LDL-C. Because each potentially
atherogenic lipoprotein particle contains a single molecule
of apo B, the apo B concentration is a direct indicator of the
number of circulating particles with atherogenic potential.
Apo B and non-HDL-C share the advantage that neither
requires fasting for accurate assessment. Non-HDL-C is
Table 3 Criteria for ASCVD risk assessment, treatment goals for atherogenic cholesterol, and levels at which to consider drug therapy
Treatment goal Consider drug therapy
Risk category Criteria
Non-HDL-C mg/dL
LDL-C mg/dL
Non-HDL-C mg/dL
LDL-C mg/dL
Low  0–1 major ASCVD risk factors
 Consider other risk indicators, if known
,130 $190
,100 $160
Moderate  2 major ASCVD risk factors
 Consider quantitative risk scoring
 Consider other risk indicators*
,130 $160
,100 $130
High  $3 major ASCVD risk factors
 Diabetes mellitus (type 1 or 2)†
B 0–1 other major ASCVD risk factors and
B No evidence of end organ damage
 Chronic kidney disease stage 3B or 4‡
 LDL-C $190 mg/dL (severe hypercholesterolemia)x
 Quantitative risk score reaching the high-risk thresholdk
,130 $130
,100 $100
Very high  ASCVD
 Diabetes mellitus (type 1 or 2)
B $2 other major ASCVD risk factors or
B Evidence of end-organ damage{
,100 $100
,70 $70
For patients with ASCVD or diabetes mellitus, consideration should be given to use of moderate or high-intensity statin therapy,
irrespective of baseline atherogenic cholesterol levels.
ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*For those at moderate risk, additional testing may be considered for some patients to assist with decisions about risk stratification. See Tables 4 and 11
and text for additional details.
†For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of ,100 mg/dL (LDL-C ,70 mg/dL) is considered a ther-
apeutic option.
‡For patients with chronic kidney disease (CKD) Stage 3B (glomerular filtration rate [GFR] 30–44 mL/min/1.73 m2) or Stage 4 (GFR 15–29 mL/min/
1.73 m2) risk calculators should not be used because they may underestimate risk. Stage 5 CKD (or on hemodialysis) is a very high-risk condition, but
results from randomized, controlled trials of lipid-altering therapies have not provided convincing evidence of reduced ASCVD events in such patients.
Therefore, no treatment goals for lipid therapy have been defined for stage 5 CKD.
xIf LDL-C is $190 mg/dL, consider severe hypercholesterolemia phenotype, which includes familial hypercholesterolemia. Lifestyle intervention
and pharmacotherapy are recommended for adults with the severe hypercholesterolemia phenotype. If it is not possible to attain desirable levels
of atherogenic cholesterol, a reduction of at least 50% is recommended. For familial hypercholesteremia patients with multiple or poorly controlled
other major ASCVD risk factors, clinicians may consider attaining even lower levels of atherogenic cholesterol. Risk calculators should not be used in
such patients.
kHigh-risk threshold is defined as $10% using Adult Treatment Panel III Framingham Risk Score for hard coronary heart disease (CHD; myocardial
infarction or CHD death), $15% using the 2013 Pooled Cohort Equations for hard ASCVD (myocardial infarction, stroke, or death from CHD or stroke), or
$45% using the Framingham long-term (to age 80) cardiovascular disease (CVD; myocardial infarction, CHD death or stroke) risk calculation. Clinicians
may prefer to use other risk calculators, but should be aware that quantitative risk calculators vary in the clinical outcomes predicted (eg, CHD events,
ASCVD events, cardiovascular mortality); the risk factors included in their calculation; and the timeframe for their prediction (eg, 5 years, 10 years, or
long-term or lifetime). Such calculators may omit certain risk indicators that can be very important in individual patients, provide only an approximate
risk estimate and require clinical judgment for interpretation.
{End-organ damage indicated by increased albumin/creatinine ratio ($30 mg/g), CKD, or retinopathy.
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universally available, requiring no additional expense, and
because apo B has not been consistently superior to non-
HDL-C in predicting ASCVD event risk.
Cholesterol-lowering drug therapies, especially statins,
alter the relationship between atherogenic cholesterol
and apo B, often lowering the cholesterol concentration
more than the apo B level. Apo B is a potential contributor
to residual ASCVD risk because it may remain elevated in
some individuals who have attained their treatment goals
for non-HDL-C and LDL-C (discussed in the followingsection). If apo B is used as an optional target for treatment,
goals are ,90 mg/dL for primary prevention and ,80 mg/
dL for those with very high risk, although measurement of
apo B is generally not necessary until the patient has been
treated to his or her goal levels for atherogenic cholesterol
(Table 2).
Clinicians may consider measuring LDL particle con-
centration as an alternative to apo B.20 The NLA Expert
Panel acknowledges that measurement of LDL particle
concentration can be useful clinically, particularly once
non-HDL-C and LDL-C goals have been attained.
Table 4 Criteria for clinical identification of the metabolic syndrome (any 3 or more of the listed components)21
Measure Categorical cut points
1. Elevated waist circumference* $40 inches ($102 cm) in men
$35 inches ($88 cm) in women
2. Elevated triglycerides (drug treatment with a triglyceride-lowering agent is an alternate
indicator†)
$150 mg/dL
3. Reduced HDL-C ,40 mg/dL in men
,50 mg/dL in women
4. Elevated blood pressure (antihypertensive drug treatment in a patient with a history of
hypertension is an alternate indicator)
Systolic $130 and/or
diastolic $85 mm Hg
5. Elevated fasting glucose (drug treatment of elevated glucose is an alternate indicator‡) $100 mg/dL
HDL-C, high-density lipoprotein cholesterol.
*American Heart Association/National Heart, Lung and Blood Institute guidelines for metabolic syndrome suggest waist circumference thresholds of
$37 inches ($94 cm) in men and$32 inches ($80 cm) in women as optional cut points for individuals or populations with increased insulin resistance,
including those of Asian descent (alternate values have also been published for other groups).5
†The most commonly used drugs for elevated triglycerides are fibric acids, nicotinic acid, and high-dose long-chain omega-3 fatty acids. A patient
taking any of these drugs may be presumed to have elevated triglycerides.
‡Most patients with type 2 diabetes mellitus will have the metabolic syndrome by these criteria.
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An elevated triglyceride level is not a target of therapy
per se, except when very high ($500 mg/dL). When
triglycerides are between 200 and 499 mg/dL, the targets
of therapy are non-HDL-C and LDL-C. When the triglyc-
eride concentration is very high ($500 mg/dL, and espe-
cially if $1000 mg/dL), reducing the concentration to
,500 mg/dL to prevent pancreatitis becomes the primary
goal of therapy.
HDL-C
The level of HDL-C is an important risk indicator and
used in risk factor counting and quantitative risk assessment.
Low HDL-C is also a component of the metabolic syn-
drome. HDL-C is not recommended as a target of therapyTable 5 Drugs that may elevate LDL-C or triglyceride concentration
Drugs that elevate LDL-C
 Some progestins
 Anabolic steroids
 Danazol
 Isotretinoin
 Immunosuppressive drugs (cyclosporine)
 Amiodarone
 Thiazide diuretics
 Glucocorticoids
 Thiazolidinediones
 Fibric acids (in severe hypertriglyceridemia)
 Long chain omega-3 fatty acids (in severe hypertriglyceridemia,
if containing docosahexaenoic acid)
LDL-C, low-density lipoprotein cholesterol.per se, but the level is often raised as a consequence of
efforts to reduce atherogenic cholesterol through lifestyle
and drug therapies.
Metabolic syndrome
Metabolic syndrome is recognized as a multiplex risk
factor for both ASCVD and type 2 diabetes mellitus
(Table 4).21 Increased adiposity and insulin resistance appear
to be central pathophysiologic features of this cluster of inter-
related metabolic and hemodynamic disturbances including
elevations in blood pressure, triglycerides and glucose as
well as depressed HDL-C. The presence of the metabolic
syndrome indicates high potential to benefit from lifestyle
therapies, particularly weight loss if overweight/obese, and
increased physical activity. Successful lifestyle intervention
will reduce adiposity and insulin resistance, improvings
Drugs that elevate triglycerides
 Oral estrogens
 Tamoxifen
 Raloxifene
 Retinoids
 Immunosuppressive drugs (cyclosporine, sirolimus)
 Interferon
 Beta-blockers (especially non-beta 1-selective)
 Atypical antipsychotic drugs (fluperlapine, clozapine,
olanzapine)
 Protease inhibitors
 Thiazide diuretics
 Glucocorticoids
 Rosiglitazone
 Bile acid sequestrants
 L-asparaginase
 Cyclophosphamide
Table 6 Diet characteristics and diseases/disorders/altered
metabolic states that may elevate LDL-C and/or triglyceride
concentrations
Cause
Elevate
LDL-C
Elevate
triglycerides
Diet
Positive energy balance U U
High saturated fat U
High trans fats U
High glycemic load U
Excess alcohol U
Weight gain U U
Anorexia nervosa U
Diseases/disorders/altered
metabolic states
Chronic kidney disease U U
Nephrotic syndrome U U
Obstructive liver disease U
Diabetes mellitus U
Metabolic syndrome U
HIV infection U U
Autoimmune disorders U U
Hypothyroidism U U
Pregnancy U U
Polycystic ovary syndrome U U
Menopause transition with
declining estrogen levels
U U
HIV, human immunodeficiency virus; LDL-C, low-density lipopro-
tein cholesterol.
Table 7 Major risk factors for ASCVD*
1. Age
Male $45 years
Female $55 years
2. Family history of early CHD†
,55 years of age in a male first-degree relative or
,65 years of age in a female first-degree relative
3. Current cigarette smoking
4. High blood pressure ($140/$90 mm Hg or on blood
pressure medication)
5. Low HDL-C
Male ,40 mg/dL
Female ,50 mg/dL
ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart
disease; HDL-C, high-density lipoprotein cholesterol.
*Levels of non–high-density lipoprotein cholesterol and low-
density lipoprotein cholesterol are not listed because these risk factors
are used to assess risk category and treatment goals for atherogenic
lipoprotein cholesterol levels. Diabetes mellitus is not listed because
it is considered a high- or very high-risk condition for ASCVD risk
assessment purposes.
†CHD is defined as myocardial infarction, coronary death, or a cor-
onary revascularization procedure.
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risk, including the metabolic syndrome components as well
as indicators of inflammation and thrombogenicity.
Secondary causes of dyslipidemia
Some conditions or medications can produce adverse
changes in lipid levels and should be considered when
evaluating patients with dyslipidemia. Medications that
may elevate levels of LDL-C and/or triglycerides are shown
in Table 5. Conditions that may produce adverse changes in
lipid levels are summarized in Table 6.Table 8 Criteria for classification of ASCVD
 Myocardial infarction or other acute coronary syndrome
 Coronary or other revascularization procedure
 Transient ischemic attack
 Ischemic stroke
 Atherosclerotic peripheral arterial disease
B Includes ankle/brachial index ,0.90
 Other documented atherosclerotic diseases such as:
B Coronary atherosclerosis
B Renal atherosclerosis
B Aortic aneurysm secondary to atherosclerosis
B Carotid plaque, $50% stenosis
ASCVD, atherosclerotic cardiovascular disease.ASCVD risk assessment and treatment goals
based on risk category
In addition to lipoprotein lipid levels, ASCVD risk
assessment includes evaluation of other major ASCVD
risk factors (Table 7), clinical evidence of ASCVD
(Table 8), and other conditions known to be associated
with high or very high risk for an ASCVD event, including
LDL-C $190 mg/dL (severe hypercholesterolemia pheno-
type), type 1 or 2 diabetes mellitus, and chronic kidney
disease (CKD) Stage 3B or higher (glomerular filtration
rate ,45 mL/kg/1.73 m2) (Table 9). For these high- and
very high-risk groups, quantitative risk scoring will oftenunderestimate ASCVD event risk, so is generally not recom-
mended unless a validated equation for that population
subset is used.
ASCVD risk is classified into four categories, as shown
in Table 3. Risk category is used both for the purpose of
defining treatment goals for atherogenic cholesterol (as
well as apo B) and for defining the level of atherogenic
cholesterol elevation at which pharmacotherapy to lower
atherogenic cholesterol might be considered. Lifestyle ther-
apies should be emphasized and monitored in all patients
with elevated levels of atherogenic cholesterol, whether
or not pharmacotherapy for dyslipidemia management is
used. Risk assessment will often proceed according to the
steps as outlined in Table 10.
Very high risk
Those with clinical evidence of ASCVD, as defined in
Table 8, and patients with diabetes plus $2 major ASCVD
Table 9 High- or very high-risk patient groups
Quantitative risk scoring is not necessary for initial risk
assessment in patients with the following conditions:*
 Diabetes mellitus, type 1 or 2
 Chronic kidney disease, stage $3B
 LDL-C$190 mg/dL: severe hypercholesterolemia phenotype,
which includes FH
 ASCVD
ASCVD, atherosclerotic cardiovascular disease; FH, familial hyper-
cholesterolemia; LDL-C, low-density lipoprotein cholesterol.
*Patients in these categories are all at high or very high risk for an
ASCVD event and should be treated accordingly.
480 Journal of Clinical Lipidology, Vol 8, No 5, October 2014risk factors (Table 7), or evidence of end-organ damage, are
considered to be at very high risk. These patients have the
most aggressive goals for atherogenic cholesterol (non-
HDL-C ,100 mg/dL, LDL-C ,70 mg/dL). For those at
very high risk, pharmacotherapy is recommended for pa-
tients who have atherogenic cholesterol levels above goal.
In addition, pharmacotherapy with a statin is considered a
therapeutic option for those in whom atherogenic choles-
terol and apo B levels are below the goal thresholds.Table 10 Sequential steps in ASCVD risk assessment
1. Identify patients with either very high-risk or high-risk condition
Very High Risk
a. ASCVD
b. Diabetes mellitus with $2 other major ASCVD risk factors or en
High Risk
a. Diabetes mellitus with 0–1 other major ASCVD risk factors
b. Chronic kidney disease stage 3B or 4†
c. LDL-C $190 mg/dL (severe hypercholesterolemia phenotype)
2. Count major ASCVD risk factors.
a. If 0–1 and no other major indicators of higher risk, assign to low
on other known risk indicators, when present.
b. If $3 major ASCVD risk factors are present, assign to high-risk
3. If 2 major ASCVD risk factors, risk scoring should be considered a
a. If quantitative risk scoring reaches the high-risk threshold,‡ as
b. Consider assigning to high-risk category if other risk indicator
c. If, based on above steps, no indication is present to assign to
Further risk assessment is not required after identifying the highest app
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprote
*End-organ damage indicated by increased albumin/creatinine ratio ($30
†For patients with CKD stage 3B (glomerular filtration rate [GFR] 30–44 mL
should not be used because they may underestimate risk. Stage 5 CKD (or on h
controlled trials of lipid-altering therapies have not provided convincing evide
goals for lipid therapy have been defined for stage 5 CKD.
‡High-risk threshold is defined as $10% using Adult Treatment Panel III F
infarction or CHD death), $15% using the 2013 Pooled Cohort Equations for ha
$45% using the Framingham long-term (to age 80) CVD (myocardial infarction
risk calculators, but should be aware that quantitative risk calculators vary in
vascular mortality); the risk factors included in their calculation; and the timef
Such calculators may omit certain risk indicators that can be very important in i
clinical judgment for interpretation.End-stage (stage 5) CKD is associated with very high
risk for ASCVD events. However, data from RCTs of lipid-
altering therapies have not consistently shown benefits in
this group. Moreover, use of intensive lipid-lowering drug
therapies in this group to achieve low levels of atherogenic
cholesterol may not be practical. Therefore, goals for
atherogenic cholesterol levels in stage 5 CKD have not
been defined and are instead considered a matter of clinical
judgment.
High risk
Those at high risk include patients with $3 major
ASCVD risk factors or a high-risk condition, including
diabetes mellitus with 0 to 1 additional major ASCVD risk
factors, CKD stage 3B or 4, or LDL-C $190 mg/dL.
As an option for those with 2 major ASCVD risk factors,
the clinician may wish to perform quantitative risk scoring
to estimate 10-year or long-term/lifetime risk for an
ASCVD or CHD event. This will facilitate identification
of patients who may be classified as high risk in the absence
of any of the high risk conditions listed previously. The
panel considers the threshold of high risk to be as follows
for three of the most commonly used risk calculators:s.
d-organ damage*
-risk category. Consider assigning to a higher risk category based
category.
nd additional testing may be useful for some patients.
sign to high-risk category.
s are present based on additional testing (see Table 11).
high-risk, assign to moderate-risk category.
licable risk level.
in cholesterol.
mg/g), chronic kidney disease (CKD), or retinopathy.
/min/1.73 m2) or stage 4 (GFR 15–29 mL/min/1.73 m2) risk calculators
emodialysis) is a very high-risk condition, but results from randomized,
nce of reduced ASCVD events in such patients. Therefore, no treatment
ramingham Risk Score for hard coronary heart disease (CHD; myocardial
rd ASCVD (myocardial infarction, stroke or death from CHD or stroke), or
, CHD death or stroke) risk calculation. Clinicians may prefer to use other
the clinical outcomes predicted (eg, CHD events, ASCVD events, cardio-
rame for their prediction (eg, 5 years, 10 years, or long-term or lifetime).
ndividual patients, provide only an approximate risk estimate and require
Table 11 Risk indicators (other than major ASCVD risk
factors) that might be considered for risk refinement*
1. A severe disturbance in a major ASCVD risk factor, such
as multipack per day smoking or strong family history of
premature CHD
2. Indicators of subclinical disease, including coronary
artery calcium
 $300 Agatston units† is considered high risk
3. LDL-C $160 mg/dL and/or non-HDL-C $190 mg/dL
4. High-sensitivity C-reactive protein $2.0 mg/L‡
5. Lipoprotein (a) $50 mg/dL (protein) using an isoform
insensitive assay
6. Urine albumin/creatinine ratio $30 mg/g
ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart
disease; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non–
high-density lipoprotein cholesterol.
*The presence of 1 or more of the risk indicators listed may be
considered, in conjunction with major ASCVD risk factors, to reclassify
an individual into a higher risk category. Except in the case of evidence
of subclinical disease defining the presence of ASCVD, reclassification
to a higher risk category is a matter of clinical judgment. Doing so
will alter the threshold for consideration of pharmacotherapy and/or
the treatment goals for atherogenic cholesterol. Many other ASCVD
risk markers are available, but the National Lipid Association Expert
Panel consensus view is that those listed have the greatest clinical
utility.
†Or coronary artery calcium $75th percentile for age, sex, and
ethnicity. For additional information, see the Coronary Artery Calcium
Score Reference Values web tool.27
‡Because of high intraindividual variability, multiple high-
sensitivity C-reactive protein (hs-CRP) values should be obtained
before concluding that the level is elevated; hs-CRP should not be
tested in those who are ill, have an infection, or are injured. If
hs-CRP level is .10 mg/L, consider other etiologies such as infection,
active arthritis, or concurrent illness.
Jacobson et al NLA Dyslipidemia Recommendations - Part 1 481 ATP III Framingham risk calculator: $10% 10-year risk
for a hard CHD event (myocardial infarction or CHD
death);
 Pooled Cohort Equations (American College of Cardiol-
ogy/American Heart Association): $15% 10-year risk
for a hard ASCVD event (myocardial infarction, stroke,
or death from CHD or stroke); and
 Framingham long-term (30-year to age 80) risk calcu-
lator: $45% risk for CVD (myocardial infarction,
CHD death, or stroke).
It should be noted that these thresholds are not intended
to indicate ‘‘statin benefit groups,’’ (ie, those in whom statin
therapy has shown benefits regarding ASCVD event risk
reduction). Results from primary prevention RCTs have
shown that the relative risk for ASCVD events is reduced
with statin therapy compared with control groups in
whom incidence rates for ASCVD are relatively low
(approximately 5.0% to 7.5% 10-year risk projected from
rates observed over shorter observation periods).22–24 In
addition, scoring calculators based on population statistics
provide only an approximate risk estimate for individual
patients and require clinical judgment for interpretation.
This is particularly true when applied to groups that
may differ in average risk level compared with the popu-
lation from which the equations were developed. In
some patients, the ASCVD risk estimate will be in the
moderate or high category based primarily on non-lipid
risk factors such as smoking or hypertension. In such cases,
attention to these risk determinants may be of primary
importance.
The goals of therapy for those at high risk are
non-HDL-C ,130 mg/dL and LDL-C ,100 mg/dL, with
consideration given to drug therapy in those whose
atherogenic cholesterol levels are higher than these goal
levels, generally after a trial of lifestyle therapy. However,
drug treatment may be started concurrently with lifestyle
therapy in some high risk patients, such as those who are
unlikely to be able to attain goal levels of atherogenic
cholesterol without drug therapy (eg, patients with LDL-C
$190 mg/dL) or with diabetes mellitus and 0 to 1 other
major ASCVD risk factors.
Moderate risk
Individuals with 2 major ASCVD risk factors, in the
absence of conditions that place them into the high- or very
high-risk categories, are considered to be at moderate risk
(approximately 5% to ,15% 10-year risk for an ASCVD
event). Quantitative risk scoring may be performed to
identify those who should be reclassified as high risk (see
the previous section).
Categorical risk factor counting and quantitative risk
assessment provide similar results in most cases. Quanti-
tative risk scoring may be helpful to refine decisions about
risk stratification by accounting for variability in risk factor
level or intensity and interactions between age and ASCVDrisk factors.1 It also provides an estimate of absolute risk,
which may be useful as an educational tool. The NLA
Expert Panel recommends that quantitative risk scoring
should be the initial step in decision-making when there
is uncertainty about the value of initiating pharmaco-
therapy for such patients. This step should generally be
completed before investigation of secondary risk factors
because the patient incurs no additional cost. However,
most risk equations do not incorporate secondary risk fac-
tors, which may be important to consider in specific
patients.
The greatest potential utility exists for assessment
of secondary ASCVD risk factors among patients with 2
major ASCVD risk factors to identify those for whom the
threshold for consideration of pharmacotherapy could be
lowered. Factors that might be considered are shown in
Table 11. As additional data become available regarding
prediction, discrimination, and accuracy, it should be
possible to more clearly define optimal strategies for appli-
cation of these tests in clinical practice.
In some patients, 10-year risk for an ASCVD event may
be lower than the high risk threshold, but lifetime risk may
be substantially elevated. This is especially true in women
482 Journal of Clinical Lipidology, Vol 8, No 5, October 2014and young adults (,40 years of age). In such individuals,
calculation of long-term/lifetime risk may be particularly
useful as an adjunct to the 10-year ASCVD or CHD event
risk.25,26
The goals of therapy for those at moderate risk are
non-HDL-C ,130 mg/dL and LDL-C ,100 mg/dL with
consideration given to drug therapy in those with values at
least 30 mg/dL above these levels (Table 3). However, the
presence of one or more secondary risk factors may prompt
the clinician to consider drug therapy for a patient in whom
atherogenic cholesterol level is higher than the goal level.
Low risk
Individuals with 0 or 1 major ASCVD risk factors are
generally at low risk for an ASCVD event (,5% 10-year
ASCVD event risk). Quantitative risk scoring is not
typically necessary for such patients. Lifestyle therapies
are the primary modalities for management of atherogenic
cholesterol levels in such patients, although consideration
may be given to pharmacotherapy in those with non-HDL-C
190 to 219 mg/dL (LDL-C 160 to 189 mg/dL). Also, in some
individuals, a severe disturbance in a single major ASCVD
risk factor (eg, strong family history of CHD or multipack
per day smoking), a known disturbance in a secondary risk
factor (eg, lipoprotein (a) $50 mg/dL), or evidence of
subclinical disease (eg, coronary artery calcium [CAC]
$300 Agatston units27) (Table 11) might justify classifying
the patient into the moderate or the high-risk category,
prompting consideration of pharmacotherapy at lower levels
of atherogenic cholesterol. If information about secondary
risk factors or subclinical disease is known for such patients,
this should be considered when assigning the risk category
and in making decisions about the use of pharmacotherapy.Figure 1 Model of steps in lifestyle therapies. *For people at high or v
started concomitantly with lifestyle therapies. For other patients, a trial o
therapy. †In most cases, goal levels should be achieved in approximateApplication of lifestyle and drug therapies
intended to reduce morbidity and mortality
associated with dyslipidemia
Lifestyle therapies
Figure 1 shows a model of the steps in application of
lifestyle therapies. For patients at low or moderate risk, life-
style therapies should be given an adequate trial (at least
3 months) before initiation of drug therapy. In patients at
very high risk, drug therapy may be started concurrently
with lifestyle therapies. This may also be the case for
selected patients in the high-risk category if the clinician
feels it is unlikely that lifestyle therapies alone will be suf-
ficient to reach goal, or if the patient has a high risk condi-
tion such as diabetes mellitus or CAC$300 Agatston units.
Visit 1
Lifestyle therapies include a diet low in saturated fat
(,7% of energy), moderate or higher intensity physical
activity ($150 minutes per week), and weight loss (5% to
10% of body weight) for those who are overweight or obese.
Where available, referral to a registered dietitian nutritionist
(RDN) is recommended to facilitate dietary modification
and to an exercise specialist for guided instruction on a
suitable exercise program.
Visit 2
If sufficient progress is not made toward achieving
atherogenic cholesterol goals, consideration may be given
to the use of dietary adjuncts, including plant sterols/stanols
(2 to 3 g/d) and viscous fibers (5 to 10 g/d). Dietary and
other lifestyle recommendations should be reinforcedery risk for ASCVD in whom drug therapy is indicated, it may be
f lifestyle therapies should be undertaken before initiation of drug
ly 6 months. RDN, registered dietitian nutritionist.
Figure 2 Progression of atherogenic cholesterol-lowering drug therapy. *A moderate- or high-intensity statin should be first-line drug
therapy for treatment of elevated levels of atherogenic cholesterol, unless contraindicated. In a patient with very high triglycerides
($500 mg/dL), a triglyceride-lowering drug may be considered for first-line use to prevent pancreatitis. Other atherosclerotic cardiovas-
cular disease risk factors should be managed appropriately in parallel. †In most cases, goal levels should be achieved in approximately
6 months.
Table 12 Intensity of statin therapy*
High-intensity daily
dosage Y LDL-C $50%
Moderate-intensity daily
dosage Y LDL-C 30% to ,50%
Atorvastatin 40–80 mg Atorvastatin 10–20 mg
Rosuvastatin 20–40 mg Fluvastatin 40 mg bid
Fluvastatin XL 80 mg
Lovastatin 40 mg
Pitavastatin 2–4 mg
Pravastatin 40–80 mg
Rosuvastatin 5–10 mg
Simvastatin 20–40 mg
bid, twice per day; LDL-C, low-density lipoprotein cholesterol.
*Individual responses to statin therapy should be expected to vary
in clinical practice. Moderate- or high-intensity statin therapy is
preferred unless not tolerated.
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mended.
Visit 3
If goal levels of atherogenic cholesterol have been
attained, responses to therapy should be monitored at
intervals of 6 to 12 months. If goal levels have not been
attained and the patient’s levels remain above the threshold
for consideration of drug therapy, drug treatment might be
initiated.
Cholesterol-lowering drug therapies
Figure 2 shows a model for progression of cholesterol-
lowering drug therapy. When used, drug therapy should
generally be initiated with moderate to high intensity statin
therapy to take advantage of demonstrated ASCVD risk-
reduction benefits.11,28–30
Patient-centered approach
Before initiation of lipid-lowering drug therapy for
ASCVD risk reduction, the clinician should have a discus-
sion with the patient about treatment objectives as well as
the potential for adverse effects, possible interactions with
other drugs or dietary supplements, lifestyle and medication
adherence, and patient preferences. Drug therapy for
elevated levels of atherogenic cholesterol is generally
maintained for an extended period. A large percentage of
patients (more than 50% in some studies) prescribed a
lipid-lowering drug discontinue refilling the prescription
within one year. Therefore, a discussion with the patient of
the importance of continued adherence to achieve ASCVD
event risk reduction is important. The clinician should
convey that alternative agents and regimens are available in
the event that side effects occur with a given medication or
dosage level.
Thresholds for consideration of drug therapy
Because of the availability of inexpensive, generic statin
medications with favorable safety and tolerability profiles,
and demonstrated efficacy for reducing ASCVD event risk,
even in relatively low-risk patients, the NLA Expert Panel
consensus view is that risk thresholds for initiating drug
treatment should be lowered as compared with the NCEP
ATP III.1,10 However, although these medications may be
relatively inexpensive and well-tolerated, overuse wouldresult in unnecessary side effects and ancillary costs (eg,
physician visits, laboratory testing). Recommendations on
such matters always involve a tradeoff between sensitivity
(capturing the greatest fraction of the potential risk reduc-
tion in the population) and specificity (minimizing the num-
ber treated who would not have experienced an ASCVD
event). The thresholds selected represent the consensus
views of the NLA Expert Panel. Some clinicians may prefer
to prescribe drug therapy (mainly statin treatment) to pa-
tients with lower levels of risk or atherogenic cholesterol.
Such an approach may be considered based on clinical
judgment and patient preferences in light of data from pri-
mary prevention RCT data showing ASCVD event risk
reduction with statin therapy compared with control groups
with projected 10-year ASCVD event rates as low as
approximately 5% to 7.5%.22–24
Initiation of drug therapy
Unless contraindicated, first-line drug therapy for treat-
ment of elevated atherogenic cholesterol levels is a moder-
ate- or high-intensity statin (see Table 12 for statin intensity
categories). A moderate-intensity statin will generally lower
LDL-C by 30% to ,50% and a high-intensity statin
by $50%, although individual patient responses should
be expected to vary considerably. Some clinicians prefer
to start with a high-intensity statin and reduce the dosage
if the patient experiences intolerance. Others prefer to
start with a moderate-intensity statin and titrate upward if
additional lowering of atherogenic cholesterol is desired.
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experience side effects, it is important for the clinician to
apply the strategy that he or she feels will produce the great-
est likelihood of long-term adherence in a given patient.
Some patients have contraindications for, or intolerance
to, statin therapy. For such patients, non-statin drug therapy
may be considered. Non-statin drug classes for lipid man-
agement include cholesterol absorption inhibitors, bile acid
sequestrants, fibric acids, long-chain omega-3 fatty acid
concentrates, and nicotinic acid. Bile acid sequestrants,
fibric acids, and nicotinic acid have been shown to reduce
CHD or ASCVD event rates in placebo-controlled
RCTs.1,31–35 A summary of the lipid effects of the main
classes of drugs available in the United States for treatmentTable 13 Drugs affecting lipoprotein metabolism
Drug class, agents, and
daily doses Lipid/lipoprotein effects
Statins* LDL-C Y18–55%
Non-HDL-C Y15–51%
HDL-C [5–15%
TG† Y7–30%
Bile acid sequestrants‡ LDL-C Y15–30%
Non-HDL-C Y4–16%
HDL-C [3–5%
TG [0–10%
Nicotinic acidx LDL-C Y5–25%
Non-HDL-C Y8–23%
HDL-C [15–35%
TG Y20–50%
Fibric acidsjj LDL-C{ Y5–[20%
Non-HDL-C Y5–19%
HDL-C [10–20%
TG Y20–50%
Cholesterol absorption inhibitor LDL-C Y13–20%
Non-HDL-C Y14–19%
HDL-C [3–5%
TG Y5–11%
Long-chain omega-3 fatty
acid drugs
LDL-C{ Y6%–[25%
Non-HDL-C Y5–14%
HDL-C Y5%–[7%
TG Y19–44%
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein
cholesterol; TG, triglycerides.
*See Table 12 for a description of statins and doses.
†TG reduction with statins, particularly high-potency statins, is
higher in patients with hypertriglyceridemia, producing reductions in
the range of 20% to 50%.
‡Cholestyramine (4–16 g), colestipol (5–20 g), and colesevelam
(2.6–3.8 g).
xImmediate-release (crystalline) nicotinic acid (1.5–3 g), extended-
release nicotinic acid (1–2 g), and sustained-release nicotinic acid
(1–2 g).
jjGemfibrozil, fenofibrate, and fenofibric acid.
{For fibric acids and long-chain omega-3 fatty acid drugs, LDL-C
may increase in patients with very high TG, except for omega-3 prod-
ucts that contain eicosapentaenoic acid only, and no docosahexaenoic
acid.of dyslipidemia is shown in Table 13. Two additional
classes of medications are also available with more limited
indications for the treatment of patients with homozygous
familial hypercholesterolemia (FH): an antisense oligonu-
cleotide that targets the messenger RNA for apo B, and a
microsomal triglyceride transfer protein inhibitor.Follow-up visits
If the goal levels of atherogenic cholesterol have not been
achieved, the statin dosage may be increased, or the patient
might be switched to a more efficacious agent. If, after an
adequate trial of the highest intensity statin therapy toler-
ated, goal levels of atherogenic cholesterol have not been
achieved, the clinician may consider referral to a lipid
specialist, or addition of a second cholesterol-lowering
agent. Once goal levels of atherogenic cholesterol have
been achieved, response to therapy should be monitored
periodically, within 4 to 12 months, to confirm continued
success in maintenance of goal levels and patient adherence.
In some patients taking high-intensity statin therapy,
atherogenic cholesterol levels may drop to low levels (eg,
LDL-C ,40 mg/dL). At present, no evidence suggests
harm with such low circulating cholesterol levels, and
therapy may be continued in such patients, particularly
those at very high ASCVD event risk, in the absence of
signs or symptoms of intolerance.
Monitoring of atherogenic cholesterol levels is also
important from the perspective of the evaluation of health
care systems. Information on attainment and maintenance
of goal levels of atherogenic cholesterol allows mecha-
nisms to be implemented for providing feedback to pro-
viders regarding quality of health care delivery.Management of patients with hypertriglyceridemia
For patients with very high triglycerides ($500 mg/dL),
the primary objective of therapy is to lower the triglyceride
level to ,500 mg/dL to reduce the risk of pancreatitis. For
patients with hypertriglyceridemia who have high triglyc-
erides (200 to 499 mg/dL), the primary objective of therapy
is to lower levels of atherogenic cholesterol (non-HDL-C
and LDL-C) to reduce risk for an ASCVD event.
Lifestyle interventions are a key to efforts to reduce
triglycerides, including weight loss if overweight or obese
(initially targeting loss of 5% to 10% of body weight),
physical activity ($150 minutes per week of moderate or
higher intensity activity), and restriction of alcohol and
sugar/refined carbohydrate intakes.
For those with very high triglycerides ($500 mg/dL),
chylomicronemia will generally be present. For such
patients, a low-fat diet (,15% of energy) may be helpful
to reduce entry of new chylomicron particles into the
circulation. For patients with triglycerides ,500 mg/dL,
partial replacement of dietary carbohydrate (especially
sugars and other refined carbohydrates) with a combination
of unsaturated fats and proteins may help to reduce the
triglyceride and non-HDL-C concentrations.36,37
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hypertriglyceridemia, an agent that primarily lowers tri-
glycerides and VLDL-C (fibric acids, high-dose [2 to 4 g/d]
long-chain omega-3 fatty acids, or nicotinic acid) should be
the first-line agent if the fasting triglyceride concentration
is $1000 mg/dL, because these will generally produce the
largest reductions in triglycerides. For patients with tri-
glycerides 500 to 999 mg/dL, a triglyceride-lowering agent
or a statin (if no history of pancreatitis) may be reasonable
first-line drug options.
For patients with high triglycerides (200 to 499 mg/dL),
a statin will generally be first-line drug therapy. Statins are
the most effective agents for reducing levels of atherogenic
cholesterol and apo B, and evidence from hypertriglyceri-
demic subgroups in RCTs shows that statins lower ASCVD
event risk in patients with elevated triglycerides in this
range.38 If maximum tolerated statin therapy does not lower
non-HDL-C below goal levels in patients with triglycerides
200 to 499 mg/dL, adding an agent that primarily lowers
triglycerides and VLDL-C may help to achieve atherogenic
cholesterol goals. Subgroup analyses from cardiovascular
outcomes studies provide suggestive evidence of reduced
ASCVD event risk with the addition of a triglyceride-
lowering agent to statin therapy, particularly in patients
with the combination of elevated triglycerides and low
HDL-C.39–41
Statin intolerance and side effects
Symptoms reportedwith statin use includemainlymuscle-
related complaints (myalgias), although there have been some
anecdotal reports of short-term memory impairment.42–44
Observational studies have failed to find significant evidence
for memory loss in those on longer-term statin therapy. It is
important to remember that musculoskeletal complaints are
common in elderly patients without statin therapy, so an eval-
uation of such complaints to assess other possible causes
should be undertaken before attributing such symptoms to
statin therapy. It is also common for patients to have concom-
itant therapies with the potential to interact with statins,
increasing the risk of muscle symptoms.45 For patients with
statin intolerance, symptoms may improve when the patient
is switched to a different statin. Other strategies that may be
employed include limiting the daily dosage andmodified reg-
imens such as every other day or onceweekly dosingwith sta-
tins, which have a long half-life. In some patients, it may be
possible to switch to an alternative concomitant therapy to
enhance statin tolerance. For patients who cannot tolerate a
statin with the previously discussed strategies, a non-statin
drug alone or in combination with another cholesterol-
lowering agent may be considered.
A modest increase in risk for type 2 diabetes mellitus has
been observed with statin therapy in RCTs, and higher
intensity statin therapy appears to increase risk to a greater
extent than less intensive regimens.46 The increase in dia-
betes incidence appears to occur mainly in those with
diabetes risk factors, such as themetabolic syndrome compo-
nents. However, these analyses also suggest that severalASCVD events are prevented for each excess case of dia-
betes produced by statin therapy, or higher intensity statin
therapy. Therefore, the panel recommends that glucose or
glycated hemoglobin be checked before initiation of statin
therapy and within 1 year afterward in those with diabetes
risk factors. In addition, lifestyle therapies should be empha-
sized, both to aid in lowering levels of atherogenic choles-
terol and for reducing diabetes risk.
Combination drug therapy
Therapy with a statin plus a second (or third) agent may
be considered for patients who have not reached their
treatment goals for atherogenic cholesterol levels, particu-
larly in patients with very high or high risk. The maximum
tolerated statin dosage should generally be used before
add-on therapy is considered. Much of the available data
for the effects of add-on therapy on ASCVD events are
from RCTs in which add-on therapy was administered to
patients with relatively low levels of atherogenic choles-
terol during statin treatment. Thus, limited RCT evidence
is available to guide therapy in the patient taking the high-
est tolerated dosage of a statin, whose levels of atherogenic
cholesterol remain above treatment goals.
Observational data as well as results from RCTs
comparing lower and higher intensity statin therapy, suggest
that ASCVD event risk is associated with levels of athero-
genic cholesterol, and that larger reductions in atherogenic
cholesterol levels are associated with greater ASCVD event
benefits.1,5,18,47 The association between on-treatment levels
of LDL-C (and non-HDL-C) appears to follow a log-linear
relationship, which is consistent with the view that the pri-
mary mechanism of action of statins is through reductions
in levels of atherogenic lipoproteins, reflected by reduc-
tions in circulating concentrations of atherogenic cho-
lesterol.5,10,47 Moreover, results from studies of different
approaches to cholesterol lowering suggest that the degree
of risk reduction with statin therapy for a given reduction
in atherogenic cholesterol is similar to that observed with
other cholesterol-lowering interventions, including other
medications, diet, and ileal bypass surgery.5,17,18
Therefore, until data are available from RCTs to better
define the potential benefits and risks of add-on therapies in
patients whose levels of atherogenic cholesterol remain
elevated while taking the highest tolerated dosage of a statin,
the NLA Expert Panel recommends that consideration be
given to use of combination therapy with agents that further
lower non-HDL-C and LDL-C to achieve goal levels of
atherogenic cholesterol. The recommendation also extends
to use of non-statin drug therapies, alone or in combination,
to achieve atherogenic cholesterol goals in patients who
have contraindications or are intolerant to statin therapy.
Treatment of patients with severe
hypercholesterolemia
Patients with the severe hypercholesterolemia pheno-
type (LDL-C $190 mg/dL), if untreated, have markedly
Table 14 LDL apheresis*
NLA criteria from expert panel on FH FDA-approved indication
LDL apheresis may be considered for the following patients
who, after 6 months, do not have adequate response to
maximum tolerated drug therapy:
 Functional homozygous FH with LDL-C $300 mg/dL
(or non-HDL-C $330 mg/dL)
 Functional heterozygous FH with LDL-C $300 mg/dL
(or non-HDL-C $330 mg/dL) and 0 to 1 risk factors
 Functional heterozygous FH with LDL-C $200 mg/dL
(or non-HDL-C $230 mg/dL) and high risk characteristics,
such as 2 risk factors or high lipoprotein (a) $50 mg/dL
using an isoform insensitive assay
 Functional heterozygous FH with LDL-C $160 mg/dL
(or non-HDL-C $190 mg/dL) and very high risk characteristics
(established CHD, other cardiovascular disease, or diabetes)
LDL apheresis is considered medically necessary when patients
have failed diet and maximum drug therapy from at least 2
separate classes of hypolipidemic drugs for at least 6 months
in addition to any 1 of the following criteria:
 Homozygous FH with LDL-C $500 mg/dL
 Heterozygous FH with LDL-C $300 mg/dL
 Functional heterozygous FH with LDL-C $200 mg/dL in patients
with coronary artery disease
CHD, coronary heart disease; FDA, Food and Drug Administration; FH, familial hypercholesterolemia; LDL, low-density lipoprotein; LDL-C, low-density
lipoprotein cholesterol; NLA, National Lipid Association; non-HDL-C, non–high-density lipoprotein cholesterol.
*The NLA criteria48,50 are more inclusive than the FDA-approved indication criteria. Clinicians should be aware of this with regard to reimbursement.
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ASCVD.48 Many such patients have FH, an autosomal
dominant (monogenic) form of hypercholesterolemia re-
sulting from reduced expression of LDL receptors.49 Other
forms of severe hypercholesterolemia result from produc-
tion of defective apo B that does not have normal inte-
ractivity with hepatic LDL receptors, and from gain of
function mutations in the proprotein convertase subtilisin/
kexin type 9 (PCSK9) gene.49
In some patients with severe hypercholesterolemia, it
may not be possible to achieve goal levels of atherogenic
cholesterol, even with combination drug therapy. When this
is the case, an alternative goal is to lower atherogenic
cholesterol levels by at least 50%. New classes of medica-
tions (eg, PCSK9 inhibitors) are under investigation that, if
shown to be safe and efficacious, may make attainment of
goal levels of atherogenic cholesterol practical for a greater
fraction of patients with severe hypercholesterolemia.
Mipomersen, an injectable antisense inhibitor of apo
B synthesis, when given in combination with maximum
tolerated doses of lipid-lowering therapy, can reduce
LDL-C by an additional 25% in homozygous FH patients,
but even the addition of mipomersen does not achieve the
recommended LDL-C target in the vast majority of homo-
zygous FH patients. In addition, injection site reactions,
hepatic fat, and liver enzyme elevations are common.
Lomitapide, an oral inhibitor of microsomal triglyceride
transfer protein, can also reduce LDL-C levels by up to by
50% in homozygous FH patients on maximum tolerated
lipid-lowering therapy and LDL apheresis. However, given
its mechanism of action, gastrointestinal side effects and
elevation in liver enzymes and hepatic fat are common.
Because of the risk of hepatotoxicity, mipomersen and
lomitapide are available only through Risk Evaluation and
Mitigation Strategy programs.For selected patients with severe hypercholesterolemia,
LDL apheresis may be considered. Table 14 shows the NLA
Expert Panel on FH criteria for consideration of LDL apher-
esis.48,50 These criteria are more inclusive than the Food and
Drug Administration-approved indications, which clinicians
should be aware of with regard to reimbursement.
Treatment of patients with progressive
atherosclerosis, or recurrent events, despite
evidence-based therapy
Little evidence is available from RCTs to guide
treatment of patients with progressive atherosclerosis, or
recurrent events, despite receiving high-intensity statin
therapy. The NLA Expert Panel consensus view is that
very aggressive therapy to lower atherogenic cholesterol
levels to values well below goal thresholds may be
considered for such patients, although it is acknowledged
that this approach is not clearly supported by clinical trial
evidence. Investigation of other potential causes, such as an
elevated level of lipoprotein (a) or other secondary risk
factors may be warranted. Non-lipid risk factors should be
well-controlled in such patients.
Updates to this document
Because the evidence in clinical medicine related to
lipid management is always evolving, these recommenda-
tions will undergo annual review with revision as necessary
to reflect important changes to the evidence base.
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